The DOI matches its Crossref record.
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807
Abstract
Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, at least one first-generation ligand has emerged as a reliable biomarker of 3R/4R PHF tau deposits [28].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [28]
In the citing paper
“18F-AV-1451 was originally developed to bind to paired helical filament tau in Alzheimer’s disease (Zhang et al., 2012; Chien et al., 2013; Xia et al., 2013), and has been extensively used in Alzheimer’s and non-Alzheimer’s diseases.”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Chien et al., 2013
In the citing paper
“Imaging biomarkers for cortical tau have become available.19,20”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [19]
In the citing paper
“Flortaucipir is being developed as a PET tracer for detection of the aggregated tau of AD.19,21,22,23,24”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [19]
In the citing paper
“As expected, in vitro QC-01–175 and T807 displayed a significantly lower affinity for all recombinant immobilized tau forms than the reported KD of T807 for native, aggregated tau filaments from AD brain sections (KD15 nM)”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Chien et al., 2013
In the citing paper
“However, small-molecule probes against tau oligomeric species, such as 18F-T807, have been developed and are currently in use as clinical tau PET tracers190.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [190]
Citations
Cited by
Sorted by citations
Items 501–600 of 653
Gao, M., Wang, M., & Zheng, Q. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.053 · Cited by 7
Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases
Zhang, L., Sun, H., Chen, Y., Wei, M., Lee, J., Li, F., & Ling, D. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1696 · Cited by 8
Dybing, K. M., Vetter, C. J., Dempsey, D. A., Chaudhuri, S., Saykin, A. J., & Risacher, S. L. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2024.0055 · Cited by 9
Radiosynthesis of [18F]AV1451 in pharmaceutical conditions and its biological characteristics
Salabert, A., Fontan, C., Fonta, C., Alonso, M., Loukh, N., Delisle, M. B., Tafani, M., & Payoux, P. (2017) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2017.06.032 · Cited by 8
Yasuno, F., & Minami, H. (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5522 · Cited by 7
“10 However, no study has assessed the effect of ChEIs on tau pathology in the brains of patients with AD.”
The tauopathies: Neuroimaging characteristics and emerging experimental therapies
Riley, K. J., Graner, B. D., & Veronesi, M. C. (2022) · Journal of Neuroimaging · doi:10.1111/jon.13001 · Cited by 8
Patel, S., Schmidt, K. F., Hesterman, J. Y., & Hoppin, J. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1085-7 · Cited by 7
Taming Alzheimer's disease: New perspectives, newer horizons.
Sen, D., Majumder, A., Arora, V., Yadu, N., & Chakrabarti, R. (2017) · PubMed Central · Cited by 7
Progress in Analysis of Tau Protein
Li, L., & Wang, X. (2020) · Chinese Journal of Analytical Chemistry · doi:10.1016/s1872-2040(20)60024-x · Cited by 7
Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy
Dustin, D. J., Hall, B. M., Annapragada, A., & Pautler, R. G. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.005 · Cited by 7
Ice Hockey Summit II: Zero Tolerance for Head Hits and Fighting
Smith, A. M., Stuart, M. J., Dodick, D. W., Roberts, W. O., Alford, P. W., Ashare, A. B., Aubrey, M., Benson, B. W., Burke, C. J., Dick, R. W., et al. (2015) · PM&R · doi:10.1016/j.pmrj.2015.02.002 · Cited by 9
“Non-invasive diagnostic techniques include MRI, diffusion tensor imaging (DTI), magnetic resonance spectroscopy (MRS), and PET, using ligands specific for paired helical filament (PHF)-tau [115,116].”
MethodPractical Synthesis of a Stable Precursor for Positron Emission Tomography Imaging Agent 18F-GTP1
White, N. A., Clagg, K., Sirois, L. E., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00301 · Cited by 6
Colato, E., Initiative, A. D. N., Chiotis, K., Ferreira, D., Mazrina, M. S., Lemoine, L., Mohanty, R., Westman, E., Nordberg, A. K., & Rodriguez‐Vieitez, E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210614 · Cited by 7
“The first generation of tau PET tracers includes 18F-THK5317 (also known as (S)18F-THK5117) [10] and 18F-flortaucipir (also known as 18F-AV1451 or 18F-T807) [11].”
BackgroundSynthesis of a new fluorine-18-labeled bexarotene analogue for PET imaging of retinoid X receptor
Wang, M., Davis, T., Gao, M., & Zheng, Q. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.037 · Cited by 6
Biomarkers in Frontotemporal Dementia
Rohrer, J. D., & Zetterberg, H. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.14.30 · Cited by 6
Genetic and degenerative disorders primarily causing dementia
Masdeu, J. C., & Pascual, B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00026-x · Cited by 6
Miao, C., Dong, F., Jia, L., Li, W., Wang, M., Zheng, Q., & Xu, Z. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.027 · Cited by 6
Neuroimaging Biomarkers in Alzheimer’s Disease
Tripathi, S. M., Chutia, P., & Murray, A. D. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2040037 · Cited by 7
“Furthermore, radiotracers 18 F-AV-1451 (also known as T807 and 18 F-flortaucipir) and 18-F-AV-680 (also known as T808), both benzimidazole pyrimidine derivatives, were developed [37,114] with higher affinity for tau aggregates and lower white matter retention.”
Liu, T., Ren, C., Guo, W., Zhang, X., Li, Y., Wang, Y., Zhang, Q., Chen, B., Dai, J., Yan, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117046 · Cited by 6
Villemagne, V. L., Okamura, N., & Rowe, C. C. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.05.001 · Cited by 7
The Current Role of Tau PET Imaging in Neurodegeneration
Vanderlinden, G., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.002 · Cited by 7
Imaging pathological tau in atypical parkinsonian disorders
Coakeley, S., & Strafella, A. P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000210 · Cited by 5
“Owing to the favorable pharmacokinetics of [(18)F]-T807 and its selective binding to tau over Ab aggregates, as mentioned previously, initial clinical testing yielded promising results in Alzheimer’s disease and mild cognitively impaired patients [23].”
BackgroundResultThe Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly
Kollack‐Walker, S., Liu, C. Y., & Fleisher, A. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.010 · Cited by 6
Huang, Y.-Y., Chiu, M., Yen, R., Tsai, C.-L., Hsieh, H.-Y., Chiu, C., Wu, C., Hsin, L., Tzen, K., Cheng, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217384 · Cited by 5
Precision health in Alzheimer disease: Risk assessment‐based strategies
Azar, J., Salama, M., Chidambaram, S. B., Al‐Balushi, B., Essa, M. M., & Qoronfleh, M. W. (2021) · Precision Medical Sciences · doi:10.1002/prm2.12036 · Cited by 7
“sion tomography imaging agent, [F-18]-T807, targeting the 3R/4R isoform.(26) Aβ and tau are found in both AD and cognitively normal people.”
BackgroundCurrent trends in advanced imaging modalities for the early diagnosis of Alzheimer's disease
Zhang, X., & Xue, P. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111628 · Cited by 4
Early syndecan-4 upregulation predicts cognitive and pathological trajectories in Alzheimer disease
Tarawneh, R. M., Moulder, K. L., Topouza, D. G., Kar, A., Qian, H., Pankratz, V. S., Timsina, J., Franklin, E. E., Schindler, S. E., Perrin, R. J., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02043-2 · Cited by 5
“In vivo brain tau-PET imaging was performed using 18 F-AV-1451 (Avid Radiopharmaceuticals) in a subset of participants ( n = 302) using the standard protocol [40].”
Tau and Alzheimer’s Disease: Molecular Mechanisms and Treatment Approaches
Reiss, A. B., Muhieddine, D., Leon, A. Z. D., Voloshyna, I., Gomolin, I. H., & Pinkhasov, A. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-01092-y · Cited by 4
Gonzalez, C., Mimmack, K. J., Amariglio, R. E., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220885 · Cited by 4
“Freesurfer(version 5.3.0) [20] was used to express specific binding with region of interest (ROI) as the standardized uptake value ratio (SUVR) to cerebellar grey as previously described [21, 22].”
InfluentialDaneshvar, D. H., & McKee, A. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00016-1 · Cited by 3
Biomarkers of Alzheimer’s Disease
Saeed, U., Swardfager, W., Black, S. E., & Masellis, M. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_8 · Cited by 4
Schaeverbeke, J. M., Luckett, E. S., Gabel, S., Reinartz, M., Meyer, S. D., Cleynen, I., Sleegers, K., Broeckhoven, C. V., Bormans, G. M., Serdons, K., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12227 · Cited by 5
Goyzueta-Mamani, L. D., Chávez‐Fumagalli, M. Á., Alvarez, K. L. F., Aguilar-Pineda, J. A., Nieto-Montesinos, R., Dávila-Del-Carpio, G., Vera-López, K. J., & Cardenas, C. L. L. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220408114129 · Cited by 3
Newberg, A. B., Coble, R., Khosravi, M., & Alavi, A. A. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.009 · Cited by 4
Tau positron emission tomography in tauopathies: A narrative review
Lee, H., Gu, Y., Seo, S. W., & Moon, S. H. (2023) · Precision and Future Medicine · doi:10.23838/pfm.2023.00016 · Cited by 4
Takahata, K., Kato, M., Mimura, M., Shimada, H., Higuchi, M., & Suhara, T. (2016) · Higher Brain Function Research · doi:10.2496/hbfr.35.276 · Cited by 4
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Yeung, L., Hale, C., Last, B. S., Andrews, H., Sloan, R. P., Honig, L. S., Small, S. A., & Brickman, A. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.010 · Cited by 4
A Study on PHF-Tau Network Effected by Apolipoprotein E4
Li, Y., Yao, Z., Yang, Y., Zhao, F., Fu, Y., Zou, Y., Hu, B., & Initiative, A. D. N. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520971414 · Cited by 4
“The PHF-Tau was an attractive target for AD/MCI diagnosis and treatment.(3) Arnold et al revealed that accumulations of PHF-Tau neuro tangles in brain have been found in cases of definite AD.”
BackgroundBiomarker Modelling of Early Molecular Changes in Alzheimer’s Disease
Paterson, R. W., Toombs, J., Slattery, C. F., Schott, J. M., & Zetterberg, H. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0069-9 · Cited by 5
OECD (2015) · OECD science, technology and industry policy papers · doi:10.1787/5js1t57jts44-en · Cited by 5
Nasrallah, I. M., Kuo, P. H., Nordberg, A. K., Bohnen, N. I., & Ponisio, M. R. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.24.32325 · Cited by 4
Dubbelman, M. A., Diez, I. P., Gonzalez, C., Amariglio, R. E., Becker, J. A., Chhatwal, J. P., Gatchel, J. R., Johnson, K. A., Locascio, J. J., Udeogu, O. J., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420290 · Cited by 3
Neelamegam, R., Yokell, D. L., Rice, P. A., Furumoto, S., Kudo, Y., Okamura, N., & Fakhri, G. E. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3482 · Cited by 3
Protas, H. D., Ghisays, V., Goradia, D. D., Bauer, R., Devadas, V., Chen, K., Reiman, E. M., & Su, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1089134 · Cited by 4
“With the advent of tau PET tracers it is possible to measure the distribution of tangle burden in vivo and characterize its progression over time (Chien et al., 2013; Dani et al., 2016; Schwarz et al., 2018).”
BackgroundGiarratana, A. O. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1637243 · Cited by 4
Tau positron emission tomography imaging in C9orf72 repeat expansion carriers
Ly, C. V., Koenig, L., Christensen, J. J., Gordon, B. A., Beaumont, H., Dahiya, S. M., Chen, Y.-H., Su, Y., Nelson, B., Jockel, J., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13940 · Cited by 4
“AV-1451 has been shown to bind neurofibrillary tangles and paired helical filament tau in situ [4].”
BackgroundNonamyloid Pet Biomarkers and Alzheimer'S Disease: Current and Future Perspectives
Schilling, L. P., Leuzy, A., Zimmer, E. R., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Future Neurology · doi:10.2217/fnl.14.40 · Cited by 4
Optimization and Biodistribution of [11C]-TKF, An Analog of Tau Protein Imaging Agent [18F]-THK523
Kong, Y., Guan, Y., Hua, F., Zhang, Z., Lu, X., Zhu, T., Zhao, B., Zhu, J., Li, C., & Chen, J. (2016) · Molecules · doi:10.3390/molecules21081019 · Cited by 3
The non-fluent/agrammatic variant of primary progressive aphasia
Grossman, M. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.012 · Cited by 3
Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer’s diseasePreprint
Vogel, J. W., Mattsson, N., Iturria‐Medina, Y., Strandberg, T. O., Schöll, M., Dansereau, C. L., Villeneuve, S., van der Flier, W. M., Scheltens, P., Bellec, P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/244574 · Cited by 3
A Cooperative Model for Symmetric Ligand Binding to Protein Fibrils
Smith, M. S., DeGrado, W. F., Grabe, M., & Shoichet, B. K. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00068 · Cited by 3
Tau PET: the next frontier in molecular imaging of dementia
Xia, C., & Dickerson, B. C. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000880 · Cited by 2
PET imaging in Down syndrome and Alzheimer's disease
Handen, B. L., & Christian, B. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00013-x · Cited by 2
Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future
Pijeira, M. S. O., Nunes, P. S. G., Chaviano, S. L., Diaz, A. M. A., DaSilva, J. N., Ricci‐Júnior, E., Alencar, L. M. R., Chen, X. S., & Santos‐Oliveira, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230818092634 · Cited by 2
Les phases prodromique et préclinique de la maladie d’Alzheimer
Planche, V., & Villain, N. (2024) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2024.01.005 · Cited by 2
Developing Low Molecular Weight PET and SPECT Imaging Agents
Xue, L., Jie, C. V. M. L., Desrayaud, S., & Auberson, Y. P. (2024) · ChemMedChem · doi:10.1002/cmdc.202400094 · Cited by 2
PET Tracers for Beta-Amyloid and Other Proteinopathies
Nordberg, A. K. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_8 · Cited by 2
Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer’s Disease
Wischik, C. M., Storey, J. M. D., Wischik, D., & Harrington, C. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00015-0 · Cited by 3
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 2
Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer’s Disease
Zhu, J. K., Risacher, S. L., Wishart, H. A., & Saykin, A. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_30 · Cited by 2
PET Imaging Agents for Alzheimer’s Disease
Choi, S., Plöessl, K., Zhu, L., & Kung, H. F. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_18 · Cited by 2
Kim, H., & Choe, Y. S. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3894 · Cited by 2
Alzheimer's Disease and Mild Cognitive Impairment
Jones, D. T., Bruns, M. B., & Petersen, R. C. (2018) · Wiley eBooks · doi:10.1002/9781118772034.ch21 · Cited by 3
Millar, P. R., Gordon, B. A., Luckett, P. H., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Hassenstab, J. J., Perrin, R. J., Schindler, S. E., Allegri, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.25.505251 · Cited by 2
“Tau deposition was imaged with PET using [18F]-Flortaucipir (AV-1451) (41).”
MethodClick Chemistry: The Certainty of Chance (Nobel Lecture)**
Sharpless, K. B., Finn, M. G., & Kolb, H. C. (2025) · Angewandte Chemie · doi:10.1002/ange.202501229 · Cited by 1
Self-citationAdvanced Tau Imaging in Alzheimer’s Disease and Other Types of Dementia
Tagai, K., & Higuchi, M. (2025) · Neuromethods · doi:10.1007/978-1-0716-4494-2_3 · Cited by 1
Dubbelman, M. A., Elias, U., Palmer, P., Dafni‐Merom, A., Gazit, L., Udeogu, O. J., Wang, S. X., Papp, K. V., Amariglio, R. E., Arzy, S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251334781 · Cited by 1
“37,38 A global cortical composite was the amyloid ROI.”
Katiyar, D., & Manish, M. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100126 · Cited by 1
Yang, F., Maher, M., Saxena, R., & Dutta, J. (2026) · Imaging Neuroscience · doi:10.1162/imag.a.1151 · Cited by 1
Karim, F., Biju, A. P., Liang, C., Santos, C. J., Rajarethenam, M., & Mukherjee, J. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02267-1 · Cited by 2
“[ 18 F]Flortaucipir (also known as T807 or AV-1451) was among the first tau PET tracers to show promise in evaluations of clinical AD with its strong affinity to tau aggregates [14, 46, 82].”
Tau and amyloid-β imaging with proteomics and genomics
Chinnathambi, S., Baisya, U., & Ananthanarayana, V. (2026) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2026.02.009 · Cited by 1
Wong, J., Wang, T., Datta, R., Abdollahi, R. O., Li, J., Rowe, C. C., Henley, D. B., Kolb, H. C., Saad, Z. S., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71573 · Cited by 2
“Participants forming the longitudinal cohorts in this study were As ADNI participants underwent tau PET imaging using AV1451 ( 18 F-T807, 18 F-flortaucipir, 18 F-FTP), 33 this cohort was designated as the Flortaucipir cohort.”
Self-citationApproach to the diagnosis of FTD
Dickerson, B. C. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.011 · Cited by 2
Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.003 · Cited by 1
Elgazzar, A. H., & Sarikaya, İ. (2018) · Springer eBooks · doi:10.1007/978-3-319-76156-5_8 · Cited by 1
Chapter 8. Dementia and Mild Neurocognitive Disorders
Wise, E. A., & Lyketsos, C. G. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds08 · Cited by 1
Progressive Supranuclear Palsy in 2022: recent developments and an eye to the future
Lyons, S., O’Dowd, S., Walsh, R. A., & Lynch, T. (2022) · Advances in Clinical Neuroscience & Rehabilitation · doi:10.47795/hmmc8661 · Cited by 1
Naskar, A., Jayanty, D., Head, K. Z., Khanna, G. L., Vatsalya, V., & Banerjee, A. (2023) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2023.134005 · Cited by 1
“Tau-specific PET ligands have demonstrated encouraging results in Alzheimer’s disease (AD) [28] [29] and detected the progression of AD tauopathy among individuals along the cognitive spectrum [30].”
BackgroundNeuroimaging Biomarkers in Alzheimer’s Disease and Related Disorders
Masdeu, J. C., & Pascual, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_11 · Cited by 1
Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?
Sakretz, M., Kurth, J., Teipel, S., & Krause, B. (2014) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-014-0811-0 · Cited by 1
“Neuentwickelte PET-Tracer zur sensitiven in-vivoDarstellung der τ-Pathologie zeigten in ersten Studien vielversprechende Ergebnisse [72, 73].”
BackgroundIn vivo imaging of neurodegeneration in dementia with Lewy bodies (DLB)
Onyike, C. U., & Smith, G. S. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000156 · Cited by 1
Neuroimaging Advances in Alzheimer's Disease
Schonhaut, D. R., & Rabinovici, G. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00017-2 · Cited by 1
Tau Imaging in Preclinical Alzheimer’s Disease
Edison, P. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_13 · Cited by 1
Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography
Timmers, T., van Berckel, B. N. M., Lammertsma, A. A., & Ossenkoppele, R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_15 · Cited by 1
Filippi, M., & Agosta, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-66773-3_1 · Cited by 1
Recognizing common PET patterns in neurodegenerative dementia
Chen, Y. J., Dubroff, J. G., & Nasrallah, I. M. (2017) · Applied Radiology · doi:10.37549/ar2385 · Cited by 1
Molecular imaging evidence in favor or against PDD and DLB overlap
Caminiti, S. P., & Carli, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00015-4 · Cited by 1
Sun, N., Mormino, E. C., Chen, J., Sabuncu, M. R., Yeo, B. T. T., & Initiative, A. D. N. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/462143 · Cited by 3
Novel Therapeutic Targets and Biomarkers for the Treatment of Progressive Supranuclear PalsyPreprint
Tyer, I., & Hill, A. (2020) · Preprints.org · doi:10.20944/preprints202006.0147.v1 · Cited by 1
Matsubara, K., Ibaraki, M., & Kinoshita, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1190960/v1 · Cited by 1
Tau PET visual reads find sources of tau not explained by typical Alzheimer disease pathophysiologyPreprint
Chen, C. D., Ponisio, M. R., Lang, J., Flores, S. E., Schindler, S. E., Fagan, A. M., Morris, J. C., & Benzinger, T. L. S. (2022) · medRxiv · doi:10.1101/2022.12.20.22283743 · Cited by 1
Tau-PET abnormality change along with Alzheimer’s disease: a topological perspectivePreprint
Ding, J., Shen, C., Wang, Z., Yang, Y., Fakhri, G. E., Lu, J., Liang, D., Zheng, H., Zhou, Y., & Sun, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2756518/v1 · Cited by 1
New Tools for the Evaluation of Patients With Neurodegenerative Diseases
Dickerson, B. C. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.48
Interview: Understanding schizophrenia and traumatic brain injury with MRI
Shenton, M. E. (2013) · Imaging in Medicine · doi:10.2217/iim.13.19
Rodríguez, A. C. (2015) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/16526
The contribution of molecular imaging research to innovative drug development
Shimada, H. (2014) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.54.1174
Diagnosis and treatment of dementia: Overview
Furukawa, K., Ishiki, A., Tomita, N., & Arai, H. (2014) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.54.1171
The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease
Selkoe, D. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00001-0
Metadata
- Authors
- Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C.
- Affiliations
- Siemens Molecular Imaging, Inc., Culver City, CA, USA
- University of California, Irvine (US)
- Hoag Memorial Hospital Presbyterian (US)
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-06-20
- Volume
- 34
- Issue
- 2
- Pages
- 457-468
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W4235092975
- Cited by
- 651
- References
- 0
- Citations by year
- 2026: 14 · 2025: 26 · 2024: 19 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 49 · 2019: 49 · 2018: 57 · 2017: 88 · 2016: 87 · 2015: 62 · 2014: 54 · 2013: 23
- FWCI
- 52.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- PHF-tau
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Carbolines, Female, Fluorine Radioisotopes, Frontal Lobe, Humans, Male, Middle Aged, Phosphorylation, tau Proteins, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
